Ntla stock forecast analysts’ NTLA stock forecast

US $253.00
List price US $985.000 (12% off)
777 sold
This one's trending. 12253 have already sold.
Breathe easy. Returns accepted.

Analysts’ NTLA stock forecast integrates biotech market trends, suggesting potential breakout if FDA fast-track designation arrives for NTLA- As many as 20 Wall Street analysts have an average “Strong Buy,” rating on Intellia stock, and the price target is $43.44, with the highest forecast of $91.00 and the lowest at $11.00, according to data from TipRanks. The average price forecast represents a 350.62% change from the last price of $9.64. Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address unmet medical needs. The company aims to revolutionize medicine by leveraging gene editing technology to create novel, first-in-class medicines, particularly in the field of transthyretin amyloidosis. NTLA stock forecast probabilities from quantitative models indicate a 60% chance of trading above $38 in the next 90 days, assuming no adverse regulatory headlines.